Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
15.97 -0.93 (-5.50%) 11:48 ET [NASDAQ]
15.93 x 107 16.11 x 5
Realtime by (Cboe BZX)
15.93 x 107 16.11 x 5
Realtime 16.27 -0.63 (-3.73%) 09:30 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
15.62
Day High
16.43
Open 16.43
Previous Close 16.90 16.90
Volume 188,017 188,017
Avg Vol 939,223 939,223
Stochastic %K 19.76% 19.76%
Weighted Alpha -29.61 -29.61
5-Day Change -3.25 (-16.85%) -3.25 (-16.85%)
52-Week Range 12.21 - 41.31 12.21 - 41.31
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 518,272
  • Shares Outstanding, K 30,667
  • Annual Sales, $ 91,280 K
  • Annual Income, $ -145,230 K
  • EBIT $ -115 M
  • EBITDA $ -123 M
  • 60-Month Beta -0.09
  • Price/Sales 5.70
  • Price/Cash Flow N/A
  • Price/Book 7.29

Options Overview Details

View History
  • Implied Volatility 144.15% ( -16.04%)
  • Historical Volatility 72.16%
  • IV Percentile 73%
  • IV Rank 36.13%
  • IV High 297.94% on 12/06/24
  • IV Low 57.15% on 08/23/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 28
  • Volume Avg (30-Day) 222
  • Put/Call OI Ratio 1.02
  • Today's Open Interest 7,907
  • Open Int (30-Day) 11,986

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.30
  • Number of Estimates 8
  • High Estimate -0.70
  • Low Estimate -1.65
  • Prior Year -1.64
  • Growth Rate Est. (year over year) +20.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.32 +4.70%
on 03/19/25
Period Open: 16.73
20.72 -22.59%
on 03/24/25
-0.69 (-4.12%)
since 03/10/25
3-Month
12.21 +31.37%
on 02/11/25
Period Open: 14.21
21.57 -25.64%
on 02/18/25
+1.83 (+12.88%)
since 01/10/25
52-Week
12.21 +31.37%
on 02/11/25
Period Open: 22.17
41.31 -61.17%
on 08/14/24
-6.13 (-27.65%)
since 04/10/24

Most Recent Stories

More News
Anaptys Announces Stock Repurchase Plan

ANAB : 15.97 (-5.50%)
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

ANAB : 15.97 (-5.50%)
Anaptys Announces Participation in March Investor Conferences

ANAB : 15.97 (-5.50%)
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

ANAB : 15.97 (-5.50%)
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

ANAB : 15.97 (-5.50%)
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

ANAB : 15.97 (-5.50%)
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

ANAB : 15.97 (-5.50%)
How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

One stock that might be an intriguing choice for investors right now is AnaptysBio, Inc. ANAB. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate...

ANAB : 15.97 (-5.50%)
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ANAB : 15.97 (-5.50%)
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated

Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.

ANAB : 15.97 (-5.50%)
AnaptysBio Discontinues ANB032 Development After Phase 2a Trial Fails to Meet Efficacy Endpoints

AnaptysBio halts ANB032 investment after ineffective trial results; focuses on other assets, with cash runway through 2027.Quiver AI SummaryAnaptysBio, Inc. announced that its investigational drug ANB032,...

ANAB : 15.97 (-5.50%)
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ANAB : 15.97 (-5.50%)
Anaptys Announces Participation in November and December Investor Conferences

ANAB : 15.97 (-5.50%)
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

ANAB : 15.97 (-5.50%)
Why AnaptysBio Was Such a Healthy Stock This Week

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.

ANAB : 15.97 (-5.50%)
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

A powerfully bullish new analyst take on the company helped it rally on the market.

WFC : 63.03 (-4.98%)
LLY : 704.98 (-6.47%)
ANAB : 15.97 (-5.50%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 542.28 (-3.87%)
ABBV : 168.00 (-6.58%)
ABCL : 2.00 (-8.06%)
ALNY : 221.67 (-8.88%)
AMGN : 274.97 (-5.54%)
ANAB : 15.97 (-5.50%)
AZN : 64.11 (-3.97%)
BMY : 50.18 (-6.62%)
INCY : 55.08 (-6.42%)
REGN : 542.98 (-5.85%)
VIE : 53.01 (unch)
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies...

ANAB : 15.97 (-5.50%)

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 20.95
2nd Resistance Point 19.54
1st Resistance Point 18.22
Last Price 15.97
1st Support Level 15.49
2nd Support Level 14.08
3rd Support Level 12.76

See More

52-Week High 41.31
Fibonacci 61.8% 30.19
Fibonacci 50% 26.76
Fibonacci 38.2% 23.33
Last Price 15.97
52-Week Low 12.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.